During the recent session, Novavax, Inc. (NASDAQ:NVAX)’s traded shares were 7.57 million, with the beta value of the company hitting 1.91. At the last check today, the stock’s price was $13.07, reflecting an intraday gain of 1.36% or $0.17. The 52-week high for the NVAX share is $15.00, that puts it down -14.77 from that peak though still a striking 72.99% gain since the share price plummeted to a 52-week low of $3.53. The company’s market capitalization is $1.84B, and the average trade volume was 12.43 million shares over the past three months.
Novavax, Inc. (NASDAQ:NVAX) trade information
Novavax, Inc. (NVAX) registered a 1.36% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.36% in intraday trading to $13.07, hitting a weekly high. The stock’s 5-day price performance is 192.51%, and it has moved by 236.12% in 30 days. Based on these gigs, the overall price performance for the year is 71.14%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Novavax, Inc. (NVAX) estimates and forecasts
Statistics show that Novavax, Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Novavax, Inc. (NVAX) shares have gone up 109.54% during the last six months, with a year-to-date growth rate more than the industry average at 88.72% against 13.50. In the rating firms’ projections, revenue will decrease -7.30% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 147.24M as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 74.9M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 11.55%. While earnings are projected to return 101.17% in 2024.
NVAX Dividends
Novavax, Inc. is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
